 It should be unique for each medicine and contribute to a well-sounding name.This means that antibodies with the same source and target substems are only distinguished by their prefix.Even antibodies targeting exactly the same structure are differently prefixed, such as the "ada"limumab and "go"limumab, both of which are TNF inhibitors but differ in their chemical structure.